Journal article

Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861

Roger Gilabert-Oriol, Alexander Weng, Alexandra Trautner, Christoph Weise, Daniel Schmid, Cheenu Bhargava, Nicole Niesler, Peter J Wookey, Hendrik Fuchs, Mayank Thakur

Biochemical Pharmacology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2015

Abstract

The therapeutic relevance of immunotoxins is based on the conjugation of monoclonal antibodies to toxins. In cancer therapies, the conjugated antibodies not only direct the binding of immunotoxins to cancer-specific receptors and mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. In the present study, the therapeutic antibodies Cetuximab (anti-EGFR, Erbitux(®)), Panitumumab (anti-EGFR, Vectibix(®)) and Trastuzumab (anti-HER2, Herceptin(®)) were chemically conjugated to the toxin dianthin. In the first instance, recombinant dianthin was characterized by mass spectrometry and its stability was analyzed..

View full abstract

University of Melbourne Researchers